Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rifaximin for SIBO in Abdominal Distension
NCT06518850Phase 2Not yet recruiting
- Sponsor
- Peking Union Medical College Hospital
- Start
- Aug 2024
- Primary completion
- Dec 2024
- Modality
- Small Molecules
01
Overview
A Phase 2 trial of rifaximin in Small Intestinal Bacterial Overgrowth (SIBO), sponsored by Peking Union Medical College Hospital. Planned start Aug 2024; status: not yet recruiting.
02
Drugs
rifaximin
03
Conditions
Small Intestinal Bacterial Overgrowth (SIBO)
Beyond the preview
Go deeper on NCT06518850.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06518850.